BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17766650)

  • 1. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
    Mathijssen RH; de Jong FA; Loos WJ; van der Bol JM; Verweij J; Sparreboom A
    Oncologist; 2007 Aug; 12(8):913-23. PubMed ID: 17766650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
    Loos WJ; de Jongh FE; Sparreboom A; de Wit R; van Boven-van Zomeren DM; Stoter G; Nooter K; Verweij J
    J Clin Oncol; 2006 Apr; 24(10):1499-506. PubMed ID: 16574999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.
    Hempel G; Boos J
    Oncologist; 2007 Aug; 12(8):924-6. PubMed ID: 17766651
    [No Abstract]   [Full Text] [Related]  

  • 4. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
    Loos WJ; Gelderblom H; Sparreboom A; Verweij J; de Jonge MJ
    Clin Cancer Res; 2000 Jul; 6(7):2685-9. PubMed ID: 10914710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
    Smorenburg CH; Sparreboom A; Bontenbal M; Stoter G; Nooter K; Verweij J
    J Clin Oncol; 2003 Jan; 21(2):197-202. PubMed ID: 12525510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].
    Lehne G; Bjørheim J; Saeter G
    Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1040-4. PubMed ID: 17457389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and dose individualization in cancer chemotherapy: the role of body surface area and body mass index.
    Portugal RD
    Med Hypotheses; 2005; 65(4):748-51. PubMed ID: 15979816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body surface area estimation in children using weight alone: application in paediatric oncology.
    Sharkey I; Boddy AV; Wallace H; Mycroft J; Hollis R; Picton S;
    Br J Cancer; 2001 Jul; 85(1):23-8. PubMed ID: 11437397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-sectional study comparing variation in body surface area and chemotherapy dosing in pediatric oncology using two different methods.
    Jastaniah W; Aseeri M
    J Oncol Pharm Pract; 2010 Sep; 16(3):189-93. PubMed ID: 19808711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
    Schwartz J; Toste B; Dizon DS
    Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
    Wang DD; Zhang S; Zhao H; Men AY; Parivar K
    J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of fixed dosing of new anticancer agents in phase I studies.
    Levêque D
    Anticancer Res; 2008; 28(5B):3075-7. PubMed ID: 19031959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of body weight and body surface area in dosing of anticancer agents in adult patients].
    Levêque D
    Bull Cancer; 2007 Jul; 94(7):647-51. PubMed ID: 17723945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
    Gurney H
    J Clin Oncol; 1996 Sep; 14(9):2590-611. PubMed ID: 8823340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.
    Chatelut E; White-Koning ML; Mathijssen RH; Puisset F; Baker SD; Sparreboom A
    Br J Cancer; 2012 Sep; 107(7):1100-6. PubMed ID: 22929884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal prescription method for cancer chemotherapy.
    Vriesendorp HM
    Exp Hematol; 1985; 13 Suppl 16():57-63. PubMed ID: 3857184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
    Felici A; Verweij J; Sparreboom A
    Eur J Cancer; 2002 Sep; 38(13):1677-84. PubMed ID: 12175683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.
    Pai MP
    Pharmacotherapy; 2012 Sep; 32(9):856-68. PubMed ID: 22711238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
    de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
    J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lower costs for anticancer drugs by safety margin around calculated dose and by fine-tuning on ampoule strength].
    Mertens S; de Jongh FE
    Ned Tijdschr Geneeskd; 2009; 153():B162. PubMed ID: 19785801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.